Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa before radical cystectomy for urothelial carcinoma of the bladder
ISRCTN17038127Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in transitional cell carcinoma of the bladder (TCC) and bladder cancer, sponsored by Queen Mary University of London. Primary endpoint: Pathological complete response rate. Started Jun 2021; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
transitional cell carcinoma of the bladder (TCC)bladder cancer
Beyond the preview
Go deeper on ISRCTN17038127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17038127.